ZNFX1: A Potential Drug Target for Cell Signaling and Cellular Processes

Target Name: ZNFX1

NCBI ID: G57169

ZNFX1

ZNFX1: A Potential Drug Target for Cell Signaling and Cellular Processes

ZNFX1 (ZNFX1_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and pancreas. It is a member of the ZNF2 family, which is a group of transcription factors that play a crucial role in regulating gene expression and cell function.

One of the most significant functions of ZNFX1 is its role in cell signaling. It is a positive regulator of the NF-kappa-B signaling pathway, which is a complex network of interactions that regulates various cellular processes, including inflammation, cell survival, and metabolism.

The NF-kappa-B signaling pathway is a critical pathway that regulates many cellular processes in the body. It is involved in the regulation of inflammation, pain, and cancer. ZNFX1 plays a key role in the regulation of NF-kappa-B signaling by promoting the assembly and activation of the transcription factor, nuclear factor kappa B (NF-kappa-B), which is a key component of the pathway.

In addition to its role in cell signaling, ZNFX1 is also involved in the regulation of cellular processes that are critical for cell survival. It is a regulator of the cell cycle, and it plays a role in the regulation of mitosis, meiosis, and apoptosis. It is also involved in the regulation of cell adhesion, which is critical for the maintenance of tissue structure and the development of organs.

The ZNF2 family of transcription factors includes several other proteins that are also involved in cell signaling and cellular processes. These include ZNF1, ZNF3, ZNF5, and ZNF6. ZNF1 is involved in the regulation of cell signaling, while ZNF3 and ZNF5 are involved in the regulation of cell adhesion. ZNF6 is involved in the regulation of cell cycle progression and the regulation of DNA replication.

ZNFX1 is also of interest as a potential drug target. Its involvement in the regulation of cell signaling and cellular processes makes it a potential target for the development of new therapies for a variety of diseases. For example, ZNFX1 has been shown to be involved in the regulation of cancer cell growth and has been identified as a potential therapeutic target for the treatment of pancreatic cancer.

In conclusion, ZNFX1 is a protein that plays a critical role in cell signaling and cellular processes in the body. Its involvement in the regulation of NF-kappa-B signaling pathway and its role in the regulation of cell cycle and cell adhesion make it a potential target for the development of new therapies. Further research is needed to fully understand the functions of ZNFX1 and its potential as a drug target.

Protein Name: Zinc Finger NFX1-type Containing 1

Functions: RNA-binding protein that initiates the antiviral response and is required to restrict the replication of RNA viruses (PubMed:33872655). Acts as a double-stranded RNA (dsRNA) sensor that recognizes viral RNA and then interacts with MAVS to initiate the type I interferon response (By similarity). Also required for immunity against some bacteria, such as mycobacteria (PubMed:33876776)

The "ZNFX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNFX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets